欧洲围手术期静脉血栓栓塞症预防指南:重症监护
该指南针对ICU患者静脉血栓栓塞症(VTE)预防提出推荐。尽管常规药物预防,ICU患者VTE发生率仍达4%至15%。指南推荐全院统一预防方案(Grade 1B),不推荐在已采取血栓预防措施时常规超声筛查深静脉血栓(Grade 1B)。危重患者推荐低分子肝素优于低剂量肝素(Grade 1B);严重肾功能不全者建议低剂量肝素(Grade 2C)、达肝素(Grade 2B)或减量依诺肝素(Grade 2C),可考虑监测抗Xa活性(Grade 2C)。严重肝功能障碍者需权衡出血风险。不推荐常规下腔静脉滤器用于一级预防(Grade 1C)。疑似或确诊肝素诱导的血小板减少症时须停用所有肝素(Grade 1B),并立即改用非肝素抗凝药而非单纯停药(Grade 1C)。
要点
- ICU患者尽管常规药物预防,VTE发生率仍为4%至15%,推荐全院统一预防方案(Grade 1B)。
- 已采取血栓预防措施时,不推荐常规超声筛查深静脉血栓(Grade 1B),因检出无症状DVT可能引发治疗性抗凝而增加出血风险,且未证实减少临床显著血栓事件。
- 危重患者推荐低分子肝素优于低剂量肝素进行药物预防(Grade 1B)。
- 严重肾功能不全的危重患者建议低剂量肝素(Grade 2C)、达肝素(Grade 2B)或减量依诺肝素(Grade 2C),可考虑监测抗Xa活性(Grade 2C)。
- 疑似或确诊肝素诱导的血小板减少症时须停用所有肝素(Grade 1B),并立即改用非肝素抗凝药而非单纯停药(Grade 1C)。
适用人群与场景
- ICU收治的危重患者,包括严重肾功能不全和严重肝功能障碍者。
处置流程与药物剂量
- 推荐全院统一预防静脉血栓栓塞症方案(Grade 1B)。
- 危重患者推荐低分子肝素而非低剂量肝素进行药物预防(Grade 1B)。
- 严重肾功能不全的危重患者建议低剂量肝素(Grade 2C)、达肝素(Grade 2B)或减量依诺肝素(Grade 2C)。
- 严重肾功能不全患者使用低分子肝素时可考虑监测抗Xa活性(Grade 2C)。
- 严重肝功能障碍患者使用药物预防应仔细权衡出血风险。
- 疑似或确诊肝素诱导的血小板减少症时,须停用所有形式的肝素(Grade 1B),并立即改用非肝素抗凝药而非单纯停用肝素(Grade 1C)。
红旗征与不能漏的情况
- 疑似或确诊肝素诱导的血小板减少症:须停用所有肝素(Grade 1B),并立即改用非肝素抗凝药而非单纯停药(Grade 1C)。
研究设计与关键结果
- 制定机构:欧洲多学科专家组(European guidelines on perioperative venous thromboembolism prophylaxis)。
- 方法:基于证据分级体系提出推荐,推荐等级包括Grade 1B、1C、2B、2C。
- 推荐条款:全院统一预防方案(Grade 1B);不推荐常规超声筛查DVT(Grade 1B);低分子肝素优于低剂量肝素(Grade 1B);严重肾功能不全者建议低剂量肝素(Grade 2C)、达肝素(Grade 2B)或减量依诺肝素(Grade 2C);可考虑监测抗Xa活性(Grade 2C);不推荐常规下腔静脉滤器用于一级预防(Grade 1C);疑似或确诊HIT须停用所有肝素(Grade 1B),并立即改用非肝素抗凝药(Grade 1C)。
证据类型、等级与局限
- 证据类型:指南(Eur J Anaesthesiol)。
- 推荐强度:Grade 1B、1C、2B、2C。
- 局限:原文未报告局限性。
对床旁实践的改变
- ICU药物预防VTE应优先选用低分子肝素而非低剂量肝素(Grade 1B)。
- 已采取血栓预防措施时,不应常规超声筛查深静脉血栓(Grade 1B),以避免检出无症状DVT后治疗性抗凝增加出血风险且未证实减少临床显著血栓事件。
- 严重肾功能不全的危重患者可选用低剂量肝素、达肝素或减量依诺肝素,并可考虑监测抗Xa活性。
- 不推荐常规使用下腔静脉滤器进行VTE一级预防(Grade 1C)。
- 疑似或确诊肝素诱导的血小板减少症时,须停用所有肝素并立即改用非肝素抗凝药,而非单纯停药。
指南或共识出处
- European guidelines on perioperative venous thromboembolism prophylaxis: Intensive care(Eur J Anaesthesiol)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
: Venous thromboembolism is a common and potentially life-threatening complication that occurs in 4 to 15% of patients admitted to ICUs despite the routine use of pharmacological prophylaxis. We therefore recommend an institution-wide protocol for the prevention of venous thromboembolism (Grade 1B). The routine use of ultrasonographic screening for deep vein thrombosis is not recommended when thromboprophylactic measures are in place (Grade 1B), as the detection of asymptomatic deep vein thrombosis may prompt therapeutic anticoagulation that may increase bleeding risk but has no proven reduction of clinically significant thrombotic events. In critically ill patients, we recommend pharmacological prophylaxis with low molecular weight heparin over low-dose heparin (Grade 1B). For critically ill patients with severe renal insufficiency, we suggest the use of low-dose heparin (Grade 2C), dalteparin (Grade 2B) or reduced doses of enoxaparin (Grade 2C). Monitoring of anti-Xa activity may be considered when low molecular weight heparin is used in these patients (Grade 2C). No study has prospectively evaluated the efficacy and safety of deep vein thrombosis prophylaxis in critically ill patients with severe liver dysfunction. Thus, the use of pharmacological prophylaxis in these patients should be carefully balanced against the risk of bleeding. For critically ill patients, we recommend against the routine use of inferior vena cava filters for the primary prevention of venous thromboembolism (Grade 1C). When the diagnosis of heparin-induced thrombocytopaenia is suspected or confirmed, all forms of heparin must be discontinued (Grade 1B). In these patients, immediate anticoagulation with a nonheparin anticoagulant rather than discontinuation of heparin alone is recommended (Grade 1C).
参考来源
- Duranteau J, Taccone FS, Verhamme P, et al. European guidelines on perioperative venous thromboembolism prophylaxis: Intensive care. Eur J Anaesthesiol. 2018. PMID: 29112545. doi:10.1097/EJA.0000000000000707
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。